Cargando…
Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain
Chagas disease, caused by Trypanosoma cruzi, is the main cause of dilated cardiomyopathy in the Americas. Antiparasitic treatment mostly relies on benznidazole (Bzl) due to Nifurtimox shortage or unavailability. Both induce adverse drug effects (ADE) of varied severity in many patients, leading to t...
Autores principales: | Cevey, Ágata Carolina, Mirkin, Gerardo Ariel, Penas, Federico Nicolás, Goren, Nora Beatriz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706620/ https://www.ncbi.nlm.nih.gov/pubmed/26862474 http://dx.doi.org/10.1016/j.ijpddr.2015.12.001 |
Ejemplares similares
-
Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease
por: Cevey, Ágata C., et al.
Publicado: (2017) -
IL-10/STAT3/SOCS3 Axis Is Involved in the Anti-inflammatory Effect of Benznidazole
por: Cevey, Ágata C., et al.
Publicado: (2019) -
Benznidazole Anti-Inflammatory Effects in Murine Cardiomyocytes and Macrophages Are Mediated by Class I PI3Kδ
por: Cevey, Ágata C., et al.
Publicado: (2021) -
Role of PPARs in Trypanosoma cruzi Infection: Implications for Chagas Disease Therapy
por: Hovsepian, Eugenia, et al.
Publicado: (2012) -
Treatment with a New Peroxisome Proliferator-Activated Receptor Gamma Agonist, Pyridinecarboxylic Acid Derivative, Increases Angiogenesis and Reduces Inflammatory Mediators in the Heart of Trypanosoma cruzi-Infected Mice
por: Penas, Federico Nicolás, et al.
Publicado: (2017)